Working memory training in children with neuropsychiatric disorders and borderline intellectual functioning.

No registrations found.

Ethical review	Positive opinion
Status	Pending
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON20558

Source NTR

Brief title WORM-ID

Health condition

Children with neuropsychiatric disorders and borderline intellectual functioning

Sponsors and support

Primary sponsor: Karakter kinder- en jeugdpsychiatrie **Source(s) of monetary or material Support:** Fonds Psychische Gezondheidszorg (subdivisie Antonia Wilhelmina Fonds)

Intervention

Outcome measures

Primary outcome

1. The measured difference in behavioral problems before and after training;

- 2. The measured difference in neurocognitive functioning before and after training;
- 3. The measured difference in schoolachievement before and after training.

Study procedure from A-Z:

In the following part, we will describe the whole study procedure from start to follow- up, including the rationale for the proposed measurements. In sum, there will be a selection phase, pre- and post-assessments and a follow-up. Note that an assessment in our "clinical care as usual" includes;

1. A clinical interview with the parents and the child (an intake);

- 2. A structural developmental interview;
- 3. A comprehensive set of questionnaires;
- 4. A neuropsychological assessment with an average duration of 2 2 $\frac{1}{2}$ hours;
- 5. An appointment for instruction of the training;
- 6. An appointment for evaluation.

So in sum, the post-assessment and the follow-up will be extra for the research project compared to our daily care as usual. To be comprehensive, below, we will describe the whole procedure.

Part one: Selection phase.

Scales and Questionnaires.

An extensive clinical diagnostic procedure including a structural developmental interview and a clinical interview with the parents and the child, supervised by a child and adolescent psychiatrist will be scrutinized by a clinical diagnostic procedure including:

1. In case of ADHD and/or ASS, the ADHD and/or ASS criteria according to the DSM-IV will be checked and filled out by an experienced psychologist;

2. For assessment of other comorbid psychiatric disorders, the Diagnostic Interview Schedule for Children (DISC-IV), a highly structured diagnostic instrument designed for use by nonclinicians (Berument et.al., 1999) will be included;

3. The intellectual disabilities will also be checked before participation, through five subtests

of the WISC-III-NL (Information, Vocabulary, Picture Completion, Block Design, Digit Span), (Kort et al., 2005).

Part two: Pre-treatment-assessment.

Scales and Questionnaires.

The following parameters will be assessed before treatment (45 minutes):

1. For baseline measurement of clinical improvement, the investigator will fill out the Clinical Global Impression-Global severity scale (CGI-S), a widely used instrument to assess clinical effects in intervention studies (Shaffer et.al., 2000);

2. To evaluate psychosocial functioning of the child, the Children's Global Assessment Scale (C-GAS; Shaffer et.al., 1983) will be completed;

3. The Vragenlijst voor Inventarisatie van Sociaal gedrag van Kinderen (VISK; Luteijn, Minderaa, & Jackson, 2002) in case of ASS, and the ADHD rating scale in case of ADHD will be filled out by parents and teacher;

4. For baseline measurement of improvement of executive functioning, the Behavior Rating Inventory of Executive Function checklist (BRIEF; Smidts et al., 2009), will be filled in by the parents and teachers;

5. A side-effects checklist will be filled in.

Neurocognitive functioning:

We will test 3 domains of neurocognitive functioning and academic achievements. This will take about 2 to 2 $\frac{1}{2}$ hours. After each training session training children will be questioned about the quality of training (how much fun was it to do) and about their motivation, both scaled from 0 - 10.

1. (Working) Memory (WM):

A. Visual (spatial) short term memory: Blok recall, (Pickering et al., 2001) & Visual patterns test, (Della Sala, Gray, Baddeley, & Wilson, 1997);

B. Verbal short term memory: Digit recall, (Pickering et al., 2001) & Nonword list recall, (Pickering et al., 2001);

C. Visual (spatial) working memory: Spatial span, (Alloway, 2007);

D. Verbal working memory: Listening recall, (Pickering et al., 2001) & Backward digit recall, (Pickering et al., 2001).

2. Executive Functioning (EF):

A. Response inhibition: Go-Nogo, Amsterdamse Neuropsychologische Taken (GNG/ANT; De Sonneville, 2009);

B. Attention: Sustained Attention Dots, Amsterdamse Neuropsychologische Taken (SAD/ANT; De Sonneville, 2009).

3. Fluid intelligence (non-verbal): Raven Standard progressive matrices, (Raven, Court, & Raven, 1996);

4. Academic achievements: Tempo Toets Rekenen (arithmetic), (TTR; De Vos, 1992), Brus 1 minuut (reading), (Brus & Voeten, 1973) & Story recall (daily memory), (Van der Molen, 2007).

Part three: Post-treatment assessment.

We will repeat the following questionnaires and scales and the neurocognitive tasks of the pre-treatment 1 week after the last session: ADHD and/or Autism spectrum disorder criteria according to DSM-IV, the VISK and ADHD rating scale, C-GAS, CGI-C and BRIEF.

There will be an evaluation for parents and children to discuss experiences of the treatment and answering questions with the researchers.

Part four: Follow-up.

To determine if treatment effects are lasting, decrease or increase over time, we will perform a follow-up at 6 months after the end-point of study to observe possible clinical improvements by assessing the severity of behavioral problems through the same selection of scales and questionnaires used in the post-treatment assessment. Also a selection of neurocognitive measures will be assessed: verbal and visual working memory, fluid intelligence (Raven), attention and academic achievements (see above for details of the measures).

Secondary outcome

Side effects (headache, extreme tiredness, sleepingproblems): A side effect checklist will be filled in (based on the Pittsburgh Side effects Ratingscale).

Study description

Background summary

It is important to develop evidence-based treatments for children with borderline intellectual functioning (BIF; 70 Working memory training has been shown effective in children with attentiondeficit/hyperactivity disorder. Previous studies have found significant improvements in behavioural- and neurocognitive problems, i.e. attention, hyperactivity-impulsivity, visual and verbal working memory, complex reasoning skills, visual-spatial skills and problem solving skills (Klingberg et al., 2005; Gibson et.al., 2006). Working memory training has also been

shown effective in other populations, including children with acquired brain injuries (Van 't Hooft et.al., 2007) and children with mild intellectual disabilities (MID; 50 This study will investigate the effectiveness and safety of working memory training in this double-diagnosis group in a double blind randomized controlled trial. If the Cogmed working memory training will be proven effective in this group of children, as shown by improvements in working memory and in behavioral symptoms, this treatment may contribute to a better guality of life of the patients and their families.

Study objective

1. To investigate the efficacy of Cogmed working memory training in reducing behavioral symptoms in children with neuropsychiatric disorders and borderline intellectual functioning;

2. To investigate whether WM training improves neurocognitive functioning and academic achievements in children with neuropsychiatric disorders and borderline intellectual functioning;

3. To investigate the safety of the Cogmed working memory training in this group of patients, in terms of side effects (headache, extreme tiredness, sleepingproblems).

Study design

Start pilot august 2011.

Intervention

Cogmed[©] working memory training (Klingberg et al., 2005).

Working memory training procedure: In a double blind randomized controlled trail, two groups, each containing 50 children, will be compared. One group will be treated with the Cogmed© working memory training, version R/M. One group will be treated with a control version of Cogmed. The duration of the training for the groups is 30-45 minutes, 5 days a

week for 5 weeks. The program includes visuospatial WM tasks (e.g., remembering the position of objects in a 4x4 grid), as well as verbal tasks (remembering phonemes, letters, or digits). Responses are made by clicking on displays using the computer mouse. The children will perform a variable amount of trials each training, depending on the level of the child. Difficulty level is automatically adjusted on a trial-by-trial basis to match the WM span of the child. The difficulty level will always be on the boarder of ability of the child. Compliance control will be extended by frequently uploading the performance in a log file by the aides to the personal coach. The average compliance rate (based on all age groups: toddlers, school children, adults) is around 95 %.

The control training version is exactly the same and looks the same as the WM training that will be used in the treatment condition, but with a lower WM load (i.e., less number of items to be remembered). In the control version, the level of difficulty will still depend on how well the child performs, but there is a limit of two to three items to show up, so that the child is not able to get to a higher level than 3.

Previous studies on Cogmed Working Memory training program for children above 7 years old have shown that this version functions well as a control condition (Klingberg et al., 2002a; Klingberg et al., 2005a). When asked after completing the training, children all reported they were convinced they had been training in the treatment group.

Before and after the training, all children will undergo a neurocognitive assessment (pre- en post- assessment). In the week after the last session, the post-assessment will be done and an evaluation of the training will take place. Six months after the last training session there will be a follow-up. Both conditions have been developed by Cogmed Cognitive Medical Systems AB (Stockholm, Sweden) and translated by BeterBrein, the official Licensed Practice in the Netherlands for Cogmed, represented by Kathryn Ralph (Kathryn.Ralph@Pearson.com, for more information).

Contacts

Public

Karakter, cluster LVG
 Utrechtseweg 220 Sammy L. Roording-Ragetlie Oosterbeek 6862 BC The Netherlands +31 (0)26 4002100

Scientific

Karakter, cluster LVG
 Utrechtseweg 220 Sammy L. Roording-Ragetlie Oosterbeek 6862 BC The Netherlands

Eligibility criteria

Inclusion criteria

1. Children aged between 10 years/0 months and 13 years/11 months, known in psychiatric health care and/or special education;

2. Neuropsychiatric disorders (ADHD, ASD, or a combination of those two, possibly in combination with comorbid ODD), classified by the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 2000);

3. IQ score between 70 and 85 (BIF);

4. Access to a PC with Windows Vista or Windows XP with internet connection and speakers (at home or school).

Exclusion criteria

1. Currently intensive (i.e. weekly) individual or group psychotherapy;

2. Regular use of other medication (stimulants / neuroleptics). When medication is used for ADHD, this isn't a exclusion criteria in case of 'room for improvement';

- 3. Diagnosis of one or more of the following comorbid psychiatric disorders:
- A. Major depression;
- B. Bipolar disorder;
- C. Psychotic disorder;
- D. Chronically motor tic disorder or Gilles de la Tourette;
- E. Conduct disorder;
- F. Eating disorders;
- G. Anxiety disorders.
- 4. Neurological disorders (e.g. epilepsy) in the recent two years;

- 5. Cardiovascular disease currently or in the past;
- 6. Serious motor and/or perceptual handicap;
- 7. Participation in another clinical trail simultaneously;
- 8. Insufficient motivation to follow the training;
- 9. Medical illness which needs medical treatment.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

...

NL	
Recruitment status:	Pending
Start date (anticipated):	01-09-2011
Enrollment:	100
Туре:	Anticipated

Ethics review

Positive opinion	
Date:	07-06-2011
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

ID: 36703 Bron: ToetsingOnline Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

ID
NL2798
NTR2939
NL32435.091.10
ISRCTN wordt niet meer aangevraagd.
NL-OMON36703

Study results

Summary results N/A